Scinai Immunotherapeutics Ltd. Updates Shareholder Meeting Proxy

TL;DR

Scinai (SCNI) updated its proxy for the Aug 12 shareholder meeting. Check the new docs.

AI Summary

Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on August 5, 2024, to provide a Notice to Shareholders regarding changes to its Proxy Statement. This notice pertains to the company's Extraordinary Meeting of Shareholders scheduled for Monday, August 12, 2024.

Why It Matters

Shareholders need to be aware of updated proxy materials before voting at the upcoming Extraordinary Meeting of Shareholders.

Risk Assessment

Risk Level: low — This filing is an update to proxy materials for an upcoming shareholder meeting and does not represent a significant change in business operations or financial standing.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Filer
• BiondVax Pharmaceuticals Ltd. (company) — Former company name
• August 5, 2024 (date) — Filing date
• August 12, 2024 (date) — Extraordinary Meeting of Shareholders date

FAQ

From the Filing

0001213900-24-065259.txt : 20240805 0001213900-24-065259.hdr.sgml : 20240805 20240805172933 ACCESSION NUMBER: 0001213900-24-065259 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240805 FILED AS OF DATE: 20240805 DATE AS OF CHANGE: 20240805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 241176193 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0210633-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ EXPLANATORY NOTE Attached as Exhibit 99.1 is a notice (the “ Notice to Shareholders ”) to the Company’s shareholders containing changes to the Proxy Statement for the Company’s Extraordinary Meeting of Shareholders scheduled for Monday, August 12, 2024, at 11:00 a.m. Israel time at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv, Israel, that was furnished by the Company to the Securities and Exchange Commission on Form 6-K on July 8, 2024 . This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 Exhibit Index Exhibit No. Description 99.1 Notice to Shareholders 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 5, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3 EX-99.1 2 ea021063301ex99-1_scinai.htm NOTICE TO SHAREHOLDERS Exhibit 99.1 SCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE TO SHAREHOLDERS RE. SUPPLEMENTAL CHANGES TO PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING To Be Held on August 12, 2024 On July 8, 2024, Scinai Immunotherapeutics Ltd. (the “ Company ”) the Company furnished on Form 6-K (“Original Form 6-K”) to the Securities and Exchange Commission containing a Notice and Proxy Statement in connection with the Company’s Extraordinary Meeting of Shareholders scheduled for Monday, August 12, 2024, at 11:00 a.m. Israel time at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv, Israel (the “ Meeting ”). As set forth in the Proxy Statement, one of the proposals to be considered and voted upon at the Meeting is the approval of amendments to the Company’s articles of associati